Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 15.2%

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was down 15.2% on Friday . The company traded as low as GBX 1.35 ($0.02) and last traded at GBX 1.50 ($0.02). Approximately 14,396,062 shares were traded during mid-day trading, an increase of 67% from the average daily volume of 8,641,887 shares. The stock had previously closed at GBX 1.77 ($0.02).

Hemogenyx Pharmaceuticals Trading Down 8.4 %

The stock has a market cap of £21.65 million, a PE ratio of -161.60 and a beta of 3.14. The company has a current ratio of 3.33, a quick ratio of 6.72 and a debt-to-equity ratio of 105.93. The firm has a fifty day simple moving average of GBX 1.37 and a two-hundred day simple moving average of GBX 1.46.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.